Moleculin Biotech awards director 4,000 stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Moleculin Biotech, Inc. director John M. Climaco received 4,000 stock options on November 17, 2026, with an exercise price of $6.83 per share. The options were issued in connection with his board service. Vesting is subject to continued board service and occurs on the earlier of November 17, 2027 or the date of the company’s next annual meeting. The options expire November 17, 2036; Climaco’s reported post-transaction position was 4,334 options.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (right to buy) F2, F1 | 4,000 | -- | -- |
Footnotes (2)
- F1. The options set forth in this table vest on the earlier of November 17, 2027 or the date of the Company's next annual meeting of shareholders, subject to the grantee's continued service on the Company's Board of Directors on the vesting date.
- F2. The options were issued in connection with the reporting person's Board of Director service to the Company.
Key Figures
Key Terms
Stock Options (right to buy) technical
exercise price financial
vest technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many options did Moleculin Biotech (MBRX) director John M. Climaco receive?
When do John M. Climaco’s Moleculin Biotech options vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.